Laquinimod in the treatment of multiple sclerosis: a review of the data so far
Authors:
Open Access
- 1 March 2016
- journal article
- review article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 10, 1111-1118
Abstract
Laquinimod (ABR-215062) is a new orally available carboxamide derivative, which is currently developed for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases. Its mechanism of action may comprise immunomodulatory effects on T-cells, monocytes, and dendritic cells as well as neuroprotective effects with prominent actions on astrocytes. Laquinimod was tested in Phase II and III clinical trials in RRMS at different dosages ranging from 0.1 to 0.6 mg/day. The compound was well tolerated, yet at the dosages tested only led to moderate effects on the reduction of relapse rates as primary study endpoint in Phase III trials. In contrast, significant effects on brain atrophy and disease progression were observed. While there were no significant safety signals in the clinical trials, the Committee for Medicinal Products for Human Use (CHMP) refused marketing authorization for RRMS based on the assessment of the risk–benefit ratio with regard to data from animal studies. At present, the compound is further tested in RRMS as well as CPMS and Huntington’s disease at different concentrations. Results from these trials will further inform about the clinical benefit of laquinimod in patient cohorts with a persisting, but still insufficiently met need for safe and at the same time effective oral compounds with neuroprotective effects.Keywords
This publication has 34 references indexed in Scilit:
- Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damageJournal of Neurology, Neurosurgery & Psychiatry, 2013
- Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelinationActa Neuropathologica, 2012
- Multiple sclerosisJournal of Clinical Investigation, 2012
- Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System AutoimmunityPLOS ONE, 2012
- Placebo-Controlled Trial of Oral Laquinimod for Multiple SclerosisNew England Journal of Medicine, 2012
- Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitisJournal of Neuroimmunology, 2010
- Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled studyMultiple Sclerosis Journal, 2010
- Models of autoimmune demyelination in the central nervous system: on the way to translational medicineExperimental & Translational Stroke Medicine, 2009
- Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-β k.o. and wild type miceJournal of Neuroimmunology, 2006
- CYTOCHROME P450 3A4 IS THE MAJOR ENZYME RESPONSIBLE FOR THE METABOLISM OF LAQUINIMOD, A NOVEL IMMUNOMODULATORDrug Metabolism and Disposition, 2005